Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 1;11(2):958–973. doi: 10.7150/thno.51478

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

BCT downregulates AR-FL/AR-V7 levels through the ubiquitin-proteasome pathway. (A, B) Prostate cancer cells were treated with indicated concentrations (A) and time points (B) of BCT, and cell lysates were analyzed by immunoblot with indicated antibodies. (C) Immunoblot analyses of AR-FL, AR-V7, and HSPs in 22RV1 xenograft tumors treated p.o. with vehicle or BCT. (D, E) LNCaP, C4-2B (D), and 22RV1 (E) cells were treated with cycloheximide (CHX) and BCT as indicated for indicated time periods, and immunoblots were performed with indicated antibodies. (F) 22RV1 cells were treated with 10 nM BCT and 10 μM MG132 as indicated for indicated time periods, and immunoblots were performed with indicated antibodies. (G, H) 22RV1 cell lysates treated with BCT and MG132 as indicated for 4 h were immunoprecipitated with anti-AR (G) or anti-AR-V7 (H) antibody and immunoblotted with indicated antibodies.